Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key problems that’s emerged with popular obesity shots.

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite competitor Eli Lilly’s early mover advantage, and future competition from cheaper generics.